ストックスクリーナーアプリを入手
15.85
5.46%
0.82
アフターアワーズ：
15.85
Anaptysbio Inc (ANAB) 最新ニュース
Shareholders May Not Overlook AnaptysBio Insiders Selling US$3.6m In Stock - Simply Wall St
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry - Yahoo Finance
Barclays PLC Grows Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Anaptysbio announces clearance of U.S., India, U.K. CTA for ANB020 - Reuters
Big Biotech Fund Loaded Up on Two Stocks - Barron's
Are Medical Stocks Lagging United Therapeutics (UTHR) This Year? - Yahoo Finance
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
AnaptysBio CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of “Moderate Buy” by Analysts - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
EcoR1 Capital, LLC Increases Stake in AnaptysBio Inc - GuruFocus.com
Objective long/short (ANAB) Report - Stock Traders Daily
Ecor1 Capital, Llc Acquires 6,646 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock - MarketBeat
Ecor1 Capital's Oleg Nodelman acquires $1.1m in AnaptysBio stock By Investing.com - Investing.com South Africa
Ecor1 Capital's Oleg Nodelman acquires $1.1m in AnaptysBio stock - Investing.com
Geode Capital Management LLC Increases Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Barclays PLC - Defense World
AnaptysBio stock hits 52-week low at $14.11 amid market challenges - Investing.com
How To Trade (ANAB) - Stock Traders Daily
State Street Corp Sells 60,670 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by State Street Corp - MarketBeat
JPMorgan Chase & Co. Lowers AnaptysBio (NASDAQ:ANAB) Price Target to $36.00 - Defense World
Franklin Resources Inc. Has $12.31 Million Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Truist Financial Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock Price - Defense World
AnaptysBio (NASDAQ:ANAB) Given New $36.00 Price Target at JPMorgan Chase & Co. - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Wellington Management Group LLP Grows Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio shares target cut, hold rating kept on trial failure By Investing.com - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Shares Gap UpStill a Buy? - MarketBeat
Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings) - Benzinga
AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout - Seeking Alpha
AnaptysBio (NASDAQ:ANAB) Price Target Lowered to $20.00 at Truist Financial - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Up 9.1%Here's What Happened - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Sees Significant Growth in Short Interest - Defense World
What is Wedbush’s Estimate for AnaptysBio FY2024 Earnings? - Defense World
Short Interest in AnaptysBio, Inc. (NASDAQ:ANAB) Grows By 5.8% - MarketBeat
Wedbush Has Negative Forecast for AnaptysBio FY2024 Earnings - MarketBeat
Analysts Set Expectations for AnaptysBio FY2024 Earnings - MarketBeat
Guggenheim Cuts AnaptysBio (NASDAQ:ANAB) Price Target to $36.00 - Defense World
Q1 Earnings Forecast for AnaptysBio Issued By HC Wainwright - Defense World
Charles Schwab Investment Management Inc. Has $5.37 Million Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio stock hits 52-week low at $14.2 amid market shifts - Investing.com Australia
AnaptysBio (NASDAQ:ANAB investor three-year losses grow to 55% as the stock sheds US$261m this past week - Simply Wall St
AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated - MSN
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals - MSN
AnaptysBio shares target cut, maintains Buy rating on phase study results - Investing.com UK
HC Wainwright & Co. Downgrades AnaptysBio (ANAB) - MSN
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints - Yahoo Finance
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio stock hits 52-week low at $14.2 amid market shifts By Investing.com - Investing.com South Africa
AnaptysBio reports failed Phase 2B trial, maintains cash reserves By Investing.com - Investing.com Canada
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):